Impacto orçamentário da incorporação do GeneXpert MTB/RIF para o diagnóstico da tuberculose pulmonar na perspectiva do Sistema Único de Saúde, Brasil, 2013-2017
Impacto orçamentário da incorporação do GeneXpert MTB/RIF para o diagnóstico da tuberculose pulmonar na perspectiva do Sistema Único de Saúde, Brasil, 2013-2017
Data
2017
Autores
Pinto, Márcia Ferreira Teixeira
Steffen, Ricardo
Entringer, Aline
Costa, Ana Carolina Carioca da
Trajman, Anete
Journal Title
Journal ISSN
Volume Title
Publisher
Cadernos de Saúde de Pública
Resumo
O objetivo do estudo foi estimar o impacto orçamentário do GeneXpert MTB/
RIF para o diagnóstico da tuberculose sob a perspectiva do Programa Nacio-
nal de Controle da Tuberculose, valendo-se de um modelo estático apoiado
no método epidemiológico entre 2013 e 2017. Comparou-se um teste Xpert
MTB/RIF com duas baciloscopias diagnósticas. Utilizaram-se dados epide-
miológicos, populacionais, de custos, a taxa de câmbio e bases de dados do
Sistema Único de Saúde. Foi realizada análise de sensibilidade por cenários. A
incorporação do GeneXpert MTB/RIF demandaria um montante de R$ 147
milhões em cinco anos e representaria um impacto de 23% a 26% nos dois pri-
meiros anos, e de cerca de 11% entre 2015 e 2017. Os resultados podem apoiar
os gestores brasileiros e dos países latino-americanos no planejamento e gestão
na sua decisão de incorporação da tecnologia.
The study aimed to estimate the budget impact of GeneXpert MTB/RIF for diagnosis of tuberculo- sis from the perspective of the Brazilian National Program for Tuberculosis Control, drawing on a static model using the epidemiological method, from 2013 to 2017. GeneXpert MTB/RIF was compared with two diagnostic sputum smear tests. The study used epidemiological, population, and cost data, exchange rates, and databases from the Brazilian Unified National Health System. Sensi- tivity analysis of scenarios was performed. Incor- poration of GeneXpert MTB/RIF would cost BRL 147 million (roughly USD 45 million) in five years and would have an impact of 23 to 26% in the first two years and some 11% between 2015 and 2017. The results can support Brazilian and other Latin American health administrators in planning and managing the decision on incorporating the tech- nology.
GeneXpert MTB/RIF for diagnosis of tuberculosis from the perspective of the Brazilian National Program for Tuberculosis Control, drawing on a static model using the epidemiological method, from 2013 to 2017. GeneXpert MTB/RIF was compared with two diagnostic sputum smear tests. The study used epidemiological, population, and cost data, exchange rates, and databases from the Brazilian Unified National Health System. Sensitivity analysis of scenarios was performed. Incorporation of GeneXpert MTB/RIF would cost BRL 147 million (roughly USD 45 million) in five years and would have an impact of 23 to 26% in the first two years and some 11% between 2015 and 2017. The results can support Brazilian and other Latin American health administrators in planning and managing the decision on incorporating the technology. Tuberculosis; Polymerase Chain Reaction; Diagnosis; Costs and Cost Analysis Resumen El objetivo del estudio fue estimar el impacto presupuestario del GeneXpert MTB/RIF para el diagnóstico de la tuberculosis, desde la perspectiva del Programa Nacional de Control de la Tuberculosis de Brasil, valiéndose de un modelo estático, apoyado en el método epidemiológico entre 2013 y 2017. Se comparó un test Xpert MTB/RIF con dos baciloscopias diagnósticas. Se utilizaron datos epidemiológicos, poblacionales, de costes, la tasa de cambio y bases de datos del Sistema Único de Salud. Se realizó un análisis de sensibilidad por escenarios. La incorporación del GeneXpert MTB/ RIF demandaría un montante de R$ 147 millones en cinco años y representaría un impacto de 23 a 26% durante los dos primeros años, y de cerca de un 11% entre 2015 y 2017. Los resultados pueden apoyar a los gestores brasileiros y de los países latinoamericanos en la planificación y gestión a la hora de decidir incorporar este tipo de tecnología.
The study aimed to estimate the budget impact of GeneXpert MTB/RIF for diagnosis of tuberculo- sis from the perspective of the Brazilian National Program for Tuberculosis Control, drawing on a static model using the epidemiological method, from 2013 to 2017. GeneXpert MTB/RIF was compared with two diagnostic sputum smear tests. The study used epidemiological, population, and cost data, exchange rates, and databases from the Brazilian Unified National Health System. Sensi- tivity analysis of scenarios was performed. Incor- poration of GeneXpert MTB/RIF would cost BRL 147 million (roughly USD 45 million) in five years and would have an impact of 23 to 26% in the first two years and some 11% between 2015 and 2017. The results can support Brazilian and other Latin American health administrators in planning and managing the decision on incorporating the tech- nology.
GeneXpert MTB/RIF for diagnosis of tuberculosis from the perspective of the Brazilian National Program for Tuberculosis Control, drawing on a static model using the epidemiological method, from 2013 to 2017. GeneXpert MTB/RIF was compared with two diagnostic sputum smear tests. The study used epidemiological, population, and cost data, exchange rates, and databases from the Brazilian Unified National Health System. Sensitivity analysis of scenarios was performed. Incorporation of GeneXpert MTB/RIF would cost BRL 147 million (roughly USD 45 million) in five years and would have an impact of 23 to 26% in the first two years and some 11% between 2015 and 2017. The results can support Brazilian and other Latin American health administrators in planning and managing the decision on incorporating the technology. Tuberculosis; Polymerase Chain Reaction; Diagnosis; Costs and Cost Analysis Resumen El objetivo del estudio fue estimar el impacto presupuestario del GeneXpert MTB/RIF para el diagnóstico de la tuberculosis, desde la perspectiva del Programa Nacional de Control de la Tuberculosis de Brasil, valiéndose de un modelo estático, apoyado en el método epidemiológico entre 2013 y 2017. Se comparó un test Xpert MTB/RIF con dos baciloscopias diagnósticas. Se utilizaron datos epidemiológicos, poblacionales, de costes, la tasa de cambio y bases de datos del Sistema Único de Salud. Se realizó un análisis de sensibilidad por escenarios. La incorporación del GeneXpert MTB/ RIF demandaría un montante de R$ 147 millones en cinco años y representaría un impacto de 23 a 26% durante los dos primeros años, y de cerca de un 11% entre 2015 y 2017. Los resultados pueden apoyar a los gestores brasileiros y de los países latinoamericanos en la planificación y gestión a la hora de decidir incorporar este tipo de tecnología.
Description
Palavras-chave
Tuberculose, Reação em Cadeia da Polimerase, Diagnóstico, Tuberculosis, Polymerase Chain Reaction, Diagnosis, Costs and Cost Analysis, Tuberculosis, Reacción en Cadena de la Polimerasa, Diagnóstico, Costos y Análisis de Costo
Citação
Pinto MFT, Steffen R, Entringer A, Costa ACCD, Trajman A. Impacto orçamentário da incorporação do GeneXpert MTB/RIF para o diagnóstico da tuberculose pulmonar na perspectiva do Sistema Único de Saúde, Brasil, 2013-2017 [Budget impact of the incorporation of GeneXpert MTB/RIF for diagnosis of pulmonary tuberculosis from the perspective of the Brazilian Unified National Health System, Brazil, 2013-2017]. Cad Saude Publica. 2017 Oct 9;33(9):e00214515. Portuguese. doi: 10.1590/0102-311X00214515